The study team measured circulating fragments of nuclear and mitochondrial DNA and telomeric integrity in plasma from 79 patients with axial spondyloarthritis and 88 age- and sex-matched healthy controls. They reported higher levels of cf-mtDNA and a lower DNA integrity index (ALU-247/ALU-115, referred to as DII) in the patient group compared with controls. There was also a reported trend toward a lower telomere length metric (T/S ratio) in patients relative to controls. The source did not provide additional procedural minutiae beyond those described in the abstract; any laboratory protocols or full numerical results are reported in the full manuscript and supplementary files linked to the preprint.
Short fragments and long fragments were summarized by the authors as the DII; a lower DII implies a relative increase in shorter DNA fragments. Data indicated that these altered cfDNA profiles differentiate axSpA cases from healthy volunteers at the group level, according to the investigators.
The cohort underwent psychiatric assessment with the Mini-International Neuropsychiatric Interview (M.I.N.I.) plus symptom scales (Beck Depression Inventory-II and Beck Anxiety Inventory). The authors observed that affective or anxiety disorders were substantially more frequent in the axSpA group versus healthy controls (26.6% vs. 2.3%, p<0.001). Depressive symptoms were also more common in patients (20.2% vs. 2.27%, p<0.001). When stratified by disease activity, depressive symptoms were reported more often in active disease compared with inactive disease (30.0% vs. 3.45%, p<0.001).
The investigators explored associations between psychiatric outcomes and cfDNA measures. They noted that a lower T/S ratio was associated with presence of affective disorders. In multivariable modeling, however, only C-reactive protein (CRP) emerged as an independent predictor of depressive symptom severity in the dataset, per the abstract. The source text supplies no further effect estimates in the abstract; readers should consult the full preprint for detailed models.
Authors reported sex differences across several molecular measures and clinical features. Female participants had higher T/S ratio and higher DII compared with males, and females exhibited higher cf-mtDNA overall. Disease phenotype and the frequency of hip involvement also differed by sex, according to the investigators. The abstract does not present stratified numeric values or p-values beyond noting these sex-related patterns; those details are in the full manuscript and supplementary data.
These observations suggest that sex is a relevant biological variable when interpreting circulating DNA markers in axSpA. The source does not claim mechanistic causation; the analyses are associative.
The authors linked altered circulating DNA metrics to both disease activity and psychiatric burden. Raised cf-mtDNA and reduced DII were associated with axSpA overall and with measures of disease activity reported by the study team. Lower T/S ratio was associated with affective disorders, while inflammatory status (CRP) independently predicted depressive symptom severity in multivariable analysis.
The source indicates these molecular signals could serve as candidate biomarkers for disease-related processes, but it does not claim diagnostic validity or clinical readiness. Performance metrics, thresholds for clinical use, and prospective validation were not reported in the abstract.
This was a case-control study enrolling 79 patients with axSpA and 88 matched healthy controls. Mental health evaluations used structured and validated instruments (M.I.N.I. and Beck inventories). Disease activity measures included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and ASDAS-CRP. Ethical approval and informed consent were obtained under the Ethics Committee of the Institute of Rheumatology in Prague (No. 5704/2021), as declared by the authors.
The data that generated the findings are not publicly available because they contain clinical information; however, the authors state that datasets can be obtained from the corresponding author on reasonable request. Full laboratory methods, statistical modeling details and supplemental tables are referenced in the preprint and supplementary material linked to the article.
This report is a medRxiv preprint and has not completed peer review; the authors state that the findings should not yet guide clinical practice. The abstract presents associative results only; causality cannot be inferred. The summary does not include full numeric effect sizes, confidence intervals, or detailed laboratory protocols—those are available in the full manuscript and supplementary files. The source does not report prospective validation of cf-mtDNA, DII, or T/S ratio as clinical biomarkers, nor does it provide diagnostic thresholds or external cohort replication in this abstract.
Unanswered questions that remain in the source include the mechanisms linking altered circulating DNA profiles with psychiatric symptoms and disease activity, the temporal dynamics of these markers relative to flares or treatment response, and whether the observed sex differences persist in larger independent cohorts. The authors recommend further investigation; specific next steps and regulatory milestones are not specified in the abstract. The dataset access statement and declared ethical approvals are provided by the authors in the manuscript.